Pfizer stock reports a Q2 earnings beat at USD 28.43

Published on 09/25/2026 at 12:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer stock posted adjusted EPS of USD 0.77 versus USD 0.68 consensus in Q2 2026, MarketBeat reported on September 20, 2026. Full-year EPS guidance stayed at USD 2.80-3.00.

Fotorealistische unbeschriftete Pharma-Anlage bei Dämmerung, Symbolbild für Pfizer Inc — Fotorealistische Pharma-Produktionsanlage bei Dämmerung symbolisiert Pfizer Inc. mit ISIN US7170811035 im Biotech-Sektor, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) stood at USD 28.43 on the NYSE on September 24, 2026, while its second-quarter adjusted EPS beat consensus by USD 0.09. The earnings comparison remains the clearest near-term measure of whether Pfizer's newer products can offset pressure on its COVID portfolio.

Quarterly beat sets the baseline

MarketBeat reported on September 20, 2026, that Pfizer delivered adjusted EPS of USD 0.77 for the second quarter reported on August 4, 2026, against USD 0.68 expected. Quarterly revenue reached USD 15.03 billion versus USD 14.40 billion consensus, a USD 0.63 billion gap.

The revenue result also represented 2.6 percent year-over-year growth, while adjusted EPS was below the USD 0.78 reported for the comparable quarter. That combination gives the stock a more balanced earnings profile: sales improved, but per-share earnings still faced a tougher comparison.

COVID revenue keeps shrinking

At the U.S. All Stars Conference on September 22, 2026, Pfizer described a sharp change in its product mix. Investing.com reported that management guided for USD 4 billion in 2026 COVID revenue, compared with USD 6.7 billion in 2025 and USD 11 billion in 2024. The implied decline from 2024 to the 2026 guidance is 63 percent.

The same conference coverage said Pfizer's international new and acquired product portfolio reached USD 4 billion, compared with USD 0.5 billion in 2023. For investors, this is the central operating test: portfolio expansion must become large enough to counter the continuing COVID decline.

Analysts stay near the share price

MarketBeat listed a consensus Hold rating from 21 analysts on September 20, 2026, with an average 12-month price target of USD 28.3889. That target sits below Pfizer's USD 28.43 reference price, leaving the consensus close to the market quote rather than signaling a broad rerating.

Management maintained full-year 2026 adjusted EPS guidance of USD 2.80-3.00, according to MarketBeat. Pfizer's next scheduled quarterly update is November 3, 2026, when the company plans to discuss its third-quarter performance at 10:00 a.m. EST, as stated by StockTitan on September 22, 2026.

Stock remains below yearly high

Pfizer stock was USD 0.78 below its 52-week high of USD 29.21 and USD 4.85 above its 52-week low of USD 23.58 on September 24, 2026. Its market capitalization was USD 162,035,079,200, while the session volume was 32,782,056 shares.